Wet Age-related Macular Degeneration
📧 Sign up to get email alerts when something new happens for Wet Age-related Macular Degeneration.
Sign up freeTop drugs studied for this disease
-
EMA withdrawal · 2025-04-14EMA Application withdrawn: Skojoy (aflibercept) — Amgen Technology (Ireland) UC
EMA has withdrawn the marketing authorization application for Skojoy (aflibercept) submitted by Amgen Technology (Ireland) UC. The applicati…
-
CLINICAL_TRIALS trial_result · 2025-03-30Clinical Trial Update: AAVCAGsCD59 for the Treatment of Wet AMD [Phase 1]
Phase 1 clinical trial evaluating AAVCAGsCD59 for wet age-related macular degeneration has been completed.
-
CLINICAL_TRIALS trial_result · 2025-03-24Clinical Trial Update: Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD [Phase 3]
Phase 3 trial comparing HLX04-O with Ranibizumab in wet age-related macular degeneration was completed, evaluating efficacy and safety. The …
-
CLINICAL_TRIALS research · 2025-03-21Clinical Trial Update: To Evaluate the Safety and Preliminary Efficacy of Intravitreal EXG202 Injection in Patients with Wet (neovascular) Age-related Macular Degeneration (wAMD) [EARLY_Phase 1]
This clinical trial update outlines a Phase 1 intravitreal study of EXG202 for wet age-related macular degeneration, focusing on safety and …
-
CLINICAL_TRIALS trial_result · 2025-03-19Clinical Trial Update: A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 clinical effectiveness study of ONS-5010 for neovascular age-related macular degeneration has completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2025-03-19Clinical Trial Update: Safety and Tolerability of AL-001 Ophthalmic Injection in Subjects with WAMD [Phase 1, Phase 2]
Phase 1/2 trial update on the safety and tolerability of AL-001 ophthalmic injections in patients with wet age-related macular degeneration;…
-
CLINICAL_TRIALS research · 2025-03-13Clinical Trial Update: Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals [Phase 4]
This clinical trial update describes an ongoing Phase 4 study comparing 8-week versus 12-week initial follow-up treatment intervals for fari…
-
CLINICAL_TRIALS trial_result · 2025-03-04Clinical Trial Update: Cool vs Room-temperature Artificial Tears [Phase 4]
Phase 4 clinical trial comparing cool versus room-temperature artificial tears has completed; results have been posted.
-
CLINICAL_TRIALS trial_result · 2025-02-21Clinical Trial Update: Efficacy and Safety of AL-001 Ophthalmic Injection in Subjects with WAMD [Phase 2]
This update reports on a Phase 2 trial evaluating the efficacy and safety of AL-001 ophthalmic injection in wet age-related macular degenera…
-
FDA approval · 2025-02-03FDA Approved: SUSVIMO — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for SUSVIMO (ranibizumab) submitted by Genentech, Inc. The action relates to a regulatory update…
-
CLINICAL_TRIALS research · 2025-01-06Clinical Trial Update: The Effect of Phacoemulsification on the Macular Changes in Patients with Neovascular Age-related Macular Degeneration
This clinical trial update examines whether phacoemulsification (cataract surgery) impacts macular changes in patients with wet age-related …
-
CLINICAL_TRIALS trial_result · 2025-01-03Clinical Trial Update: A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O with Ranibizumab in Subjects with WAMD [Phase 3]
A Phase 3 trial evaluating HLX04-O versus Ranibizumab in wet age-related macular degeneration has completed.
-
CLINICAL_TRIALS research · 2024-12-05Clinical Trial Update: Long-term Follow-up Study of AL-001 Ophthalmic Injection in Subjects with WAMD
A long-term follow-up study of AL-001 ophthalmic injection for wet age-related macular degeneration is currently recruiting.
-
CLINICAL_TRIALS trial_result · 2024-11-20Clinical Trial Update: A Study to Test Different Doses of BI 836880 in Patients With an Eye Disease Called Wet Age-related Macular Degeneration (wAMD) [Phase 1, Phase 2]
The study tested multiple doses of BI 836880 in patients with wet age-related macular degeneration; the Phase 1/2 trial has completed and re…
-
CLINICAL_TRIALS trial_result · 2024-09-20Clinical Trial Update: Assessment of Proactive Treatments in Patients With Wet Age-related Macular Degeneration (wAMD) Which Have Never Undergone Treatment of This Particular Disease
This clinical trial update reports the completion of a Bayer-sponsored study evaluating proactive treatments for patients with wet age-relat…
-
CLINICAL_TRIALS trial_result · 2024-07-18Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate, Versus Aflibercept in Patients With Neovascular (Wet) Age-Related Macular Degeneration. [Phase 2, Phase 3]
Phase 2/Phase 3 trial comparing KSI-301, a biopolymer-conjugated anti-VEGF antibody, against aflibercept in wet age-related macular degenera…
-
CLINICAL_TRIALS trial_result · 2024-06-17Clinical Trial Update: Long-term Follow-Up Study of RGX-314 and Fellow Eye Substudy [Phase 2]
This Phase 2 clinical trial update covers long-term follow-up of RGX-314 in neovascular age-related macular degeneration, including a fellow…
-
CLINICAL_TRIALS trial_result · 2024-05-02Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) [Phase 3]
Phase 3 head-to-head trial evaluating intravitreal KSI-301 versus intravitreal aflibercept in wet age-related macular degeneration has compl…
-
CLINICAL_TRIALS trial_result · 2024-04-16Clinical Trial Update: Clinical Study on the Efficacy and Safety of BAT5906 Injection [Phase 2]
Phase 2 trial update on BAT5906 injection assessing efficacy and safety in wet age-related macular degeneration.
-
FDA approval · 2023-12-14FDA Approved: EYLEA — Supplemental Application (Regeneron Pharmaceuticals, Inc.)
The FDA approved a supplemental application for EYLEA (aflibercept) from Regeneron Pharmaceuticals, Inc.
-
FDA label_change · 2023-12-14FDA Approved: EYLEA HD — Supplemental Application (Regeneron Pharmaceuticals, Inc)
FDA approved a supplemental application for EYLEA HD (aflibercept) from Regeneron, indicating a labeling change for the high-dose formulatio…
-
CLINICAL_TRIALS trial_result · 2023-10-10Clinical Trial Update: A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD) [Phase 3]
Phase 3 trial comparing SCD411 to Eylea in wet/ neovascular age-related macular degeneration has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2023-08-31Clinical Trial Update: Efficacy and Safety of RC28-E Versus Aflibercept [Phase 3]
Phase 3 trial update comparing RC28-E to aflibercept for wet age-related macular degeneration; efficacy and safety data not yet available in…
-
EMA withdrawal · 2023-07-18EMA Application withdrawn: Susvimo (ranibizumab) — Roche Registration GmbH
The EMA indicates Susvimo (ranibizumab) application withdrawn by Roche Registration GmbH in the wet age-related macular degeneration program…
-
CLINICAL_TRIALS trial_result · 2023-06-08Clinical Trial Update: A Phase II Study of RBM-007 Alone and RBM-007 With Eylea® in Subjects With Wet Age-related Macular Degeneration [Phase 2]
Phase II study assessing RBM-007 alone and with Eylea in wet age-related macular degeneration has completed with results posted.